Physician profile
Robert Edgar Mitchell
NPI 1639252109
$7,188.66
in general payments reported to CMS, 2019-2025
31 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $294 · 2021: $970 · 2022: $1,984 · 2023: $1,059 · 2024: $913 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410 · Education: $35.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.49 |
| Education | $35.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,604.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,292.78 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $881.29 | 2020-2025 | Tremfya, Stelara |
| Erbe USA INC | $521.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $504.50 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $342.62 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $316.90 | 2022-2025 | |
| Braintree Laboratories, INC. | $205.21 | 2019-2022 | |
| Daiichi Sankyo INC. | $205.08 | 2019-2023 | Injectafer |
| Pfizer INC. | $147.06 | 2020-2025 | |
| Lilly USA, LLC | $141.78 | 2023-2025 | Omvoh |
| Celgene Corporation | $140.06 | 2020-2023 | Zeposia |
| Ethicon US, LLC | $117.12 | 2022 | |
| Intercept Pharmaceuticals, INC. | $96.50 | 2023-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $85.78 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $79.29 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $69.41 | 2019-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $64.39 | 2023-2024 | Dificid |
| Pharmacosmos Therapeutics INC. | $57.47 | 2022-2024 | Monoferric |
| Ardelyx, INC. | $47.66 | 2025 | Ibsrela |
| Celltrion USA INC. | $35.12 | 2024 | Zymfentra |
| Sandoz INC. | $34.91 | 2025 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $34.57 | 2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $34.24 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $27.83 | 2025 | Iqirvo |
| Endo Pharmaceuticals INC. | $25.44 | 2019 | |
| Shire North American Group INC | $18.51 | 2019 | |
| Novo Nordisk INC | $17.66 | 2025 | Wegovy |
| Vivus LLC | $16.49 | 2021 | |
| Olympus America INC. | $12.69 | 2019 | |
| Romark Laboratories, Lc | $10.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.